Despite considerable advances in preventative treatment during the last two decades, the
increasing burden of cardiovascular (CV) disease constitutes an urgent need for new …

Survivors of myocardial infarction (MI) are at high risk of disability and death. This is due to
infarct-related complications such as heart failure, cardiac remodeling with progressive …

Abstract Information from clinical and pharmacokinetic studies of angiotensin-converting
enzyme inhibitors (ACEIs) has come from subjects who are mostly male and Caucasian, but …

β-Blockers reduce cardiovascular death and reinfarction in patients with a history of
myocardial infarction (MI), and angiotensin-converting enzyme (ACE) inhibitors provide an …

The efficacy and tolerability of zofenopril in the treatment of essential hypertension have
been evaluated in four well-designed trials. In a dose-finding study (zofenopril 7.5 to 60 …

Activation of the renin-angiotensin-aldosterone system (RAAS) in left ventricular systolic
dysfunction is a critically important determinant in the pathophysiologic processes that lead …

Objectives. This 6-month follow-up analysis sought to assess whether the early reduction of
mortality obtained with a 6-week treatment course of lisinopril or glyceryl trinitrate, or both, in …

Healing after myocardial infarction (MI) is a well-orchestrated time-dependent process that
involves inflammation, tissue repair with extracellular collagen matrix (ECCM) deposition …

The most recent trials of ARBs in heart failure and myocardial infarction patients suggest a
role for angiotensin receptor blockers in patients with heart failure who are intolerant to ACE …

The use of angiotensin-converting enzyme (ACE) inhibitors has been generally beneficial in
the treatment of many clinical conditions characterized by a significant degree of …